Stock Track | Supernus Soars 6.6% After Smashing Q3 Earnings Estimates, Raising Full-Year Guidance

Stock Track11-05

Shares of Supernus Pharmaceuticals (NASDAQ: SUPN) soared 6.63% in after-hours trading on November 4, 2024, after the biopharmaceutical company reported blockbuster third-quarter results that crushed Wall Street estimates. The company also raised its full-year financial guidance, fueling further investor optimism.

For the third quarter, Supernus posted earnings of $0.69 per share, a remarkable beat over the consensus analyst estimate of just $0.02 per share. Revenue climbed 14% year-over-year to $175.7 million, comfortably exceeding expectations of $157.3 million.

The strong quarterly performance was driven by robust sales growth of Supernus' key products. Net sales of its ADHD treatment Qelbree surged 68% year-over-year to $62.4 million, while net sales of GOCOVRI for Parkinson's disease hypomobility rose 8% to $35.6 million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1120027310?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-05 07:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120027310","market":"hk","top_or_hot":-1,"title":"Stock Track | Supernus Soars 6.6% After Smashing Q3 Earnings Estimates, Raising Full-Year Guidance","media":"Stock Track","content":"<p>Shares of Supernus Pharmaceuticals (NASDAQ: SUPN) soared 6.63% in after-hours trading on November 4, 2024, after the biopharmaceutical company reported blockbuster third-quarter results that crushed Wall Street estimates. The company also raised its full-year financial guidance, fueling further investor optimism.</p>\n\n<p>For the third quarter, Supernus posted earnings of $0.69 per share, a remarkable beat over the consensus analyst estimate of just $0.02 per share. Revenue climbed 14% year-over-year to $175.7 million, comfortably exceeding expectations of $157.3 million.</p>\n\n<p>The strong quarterly performance was driven by robust sales growth of Supernus' key products. Net sales of its ADHD treatment Qelbree surged 68% year-over-year to $62.4 million, while net sales of GOCOVRI for Parkinson's disease hypomobility rose 8% to $35.6 million.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Supernus Soars 6.6% After Smashing Q3 Earnings Estimates, Raising Full-Year Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Supernus Soars 6.6% After Smashing Q3 Earnings Estimates, Raising Full-Year Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-05 07:42 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Supernus Pharmaceuticals (NASDAQ: SUPN) soared 6.63% in after-hours trading on November 4, 2024, after the biopharmaceutical company reported blockbuster third-quarter results that crushed ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SUPN","symbol_name":"Supernus Pharmaceuticals","start_time":0,"source_url":"","article_id":"1120027310","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120027310","pubTimestamp":1730763751,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Supernus Pharmaceuticals  soared 6.63% in after-hours trading on November 4, 2024, after the biopharmaceutical company reported blockbuster third-quarter results that crushed Wall Street estimates. The company also raised its full-year financial guidance, fueling further investor optimism.For the third quarter, Supernus posted earnings of $0.69 per share, a remarkable beat over the consensus analyst estimate of just $0.02 per share. Revenue climbed 14% year-over-year to $175.7 million,","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SUPN":"Supernus Pharmaceuticals"},"translate_title":"股票赛道Supernus在打破第三季度盈利预期并上调全年指引后飙升6.6%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SUPN":1},"content_text":"Shares of Supernus Pharmaceuticals (NASDAQ: SUPN) soared 6.63% in after-hours trading on November 4, 2024, after the biopharmaceutical company reported blockbuster third-quarter results that crushed Wall Street estimates. The company also raised its full-year financial guidance, fueling further investor optimism.\nFor the third quarter, Supernus posted earnings of $0.69 per share, a remarkable beat over the consensus analyst estimate of just $0.02 per share. Revenue climbed 14% year-over-year to $175.7 million, comfortably exceeding expectations of $157.3 million.\nThe strong quarterly performance was driven by robust sales growth of Supernus' key products. Net sales of its ADHD treatment Qelbree surged 68% year-over-year to $62.4 million, while net sales of GOCOVRI for Parkinson's disease hypomobility rose 8% to $35.6 million.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1120027310"}